The Michael J.Fox Foundation for Parkinson’s Research – Bando Target Advancement Program

The Target Advancement Program is open to industry and academic investigators proposing to build conclusive evidence to rationalize biological targets and pathways for Parkinson’s disease (PD) therapeutic development. Part of our Edmond J. Safra Core Programs for PD Research, this program will support projects focused on validating targets and defining pathways implicated in PD pathological processes and/or symptomology.

Applications should focus on studies that achieve one or more of the following goals:

  • Demonstrate pathological relevance of a target by studying its altered expression, distribution, or function in PD-relevant human tissues.
  • Demonstrate that modulation of the target or pathway in vivo in whole mammalian PD models using genetic or pharmacological manipulations yields outcomes predictive of clinical efficacy or relevance in human PD.
  • Elucidate target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
  • Replicate or further validate recently published, high-impact findings in PD biology.

For more informations viste the webiste page: Target Advancement Program

Awards: Up to $200,000 for up to 18 months

Deadline for pre-proposals: May 14, 2020

Full proposals (by invite only): September 22, 2020 

Torna in alto